Glaukos Corporation $GKOS Stock Holdings Trimmed by Legal & General Group Plc

Legal & General Group Plc lessened its position in shares of Glaukos Corporation (NYSE:GKOS) by 5.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 179,698 shares of the medical instruments supplier’s stock after selling 9,578 shares during the period. Legal & General Group Plc owned about 0.31% of Glaukos worth $20,290,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP raised its position in shares of Glaukos by 10.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock valued at $292,004,000 after acquiring an additional 336,266 shares in the last quarter. Primecap Management Co. CA boosted its holdings in Glaukos by 23.3% in the third quarter. Primecap Management Co. CA now owns 2,253,788 shares of the medical instruments supplier’s stock worth $183,796,000 after purchasing an additional 425,790 shares during the period. State Street Corp increased its stake in Glaukos by 5.3% during the second quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier’s stock valued at $215,914,000 after purchasing an additional 105,972 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Glaukos by 3.5% during the second quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock valued at $206,503,000 after purchasing an additional 68,497 shares during the last quarter. Finally, Alliancebernstein L.P. raised its holdings in shares of Glaukos by 38.5% during the third quarter. Alliancebernstein L.P. now owns 1,733,474 shares of the medical instruments supplier’s stock worth $141,365,000 after purchasing an additional 481,620 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Transactions at Glaukos

In other news, Director Leana Wen sold 1,700 shares of Glaukos stock in a transaction on Friday, May 1st. The stock was sold at an average price of $143.35, for a total transaction of $243,695.00. Following the transaction, the director directly owned 19,739 shares in the company, valued at approximately $2,829,585.65. This trade represents a 7.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Joseph E. Gilliam sold 19,573 shares of Glaukos stock in a transaction on Friday, May 1st. The shares were sold at an average price of $143.54, for a total value of $2,809,508.42. Following the transaction, the chief operating officer owned 73,419 shares in the company, valued at approximately $10,538,563.26. This trade represents a 21.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 45,930 shares of company stock valued at $6,321,363 in the last quarter. Company insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on GKOS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a report on Tuesday, April 21st. Citigroup raised their target price on shares of Glaukos from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Wall Street Zen lowered Glaukos from a “buy” rating to a “hold” rating in a report on Saturday. Needham & Company LLC increased their price target on Glaukos from $127.00 to $136.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Finally, Stifel Nicolaus set a $170.00 price target on Glaukos in a report on Thursday, April 30th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus price target of $146.17.

Glaukos Price Performance

NYSE GKOS opened at $103.08 on Monday. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $148.11. The firm has a market capitalization of $6.05 billion, a PE ratio of -31.43 and a beta of 0.83. The company’s 50 day simple moving average is $121.31 and its 200 day simple moving average is $114.45. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. The firm had revenue of $150.57 million during the quarter, compared to the consensus estimate of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The firm’s revenue for the quarter was up 41.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.22) earnings per share. As a group, equities research analysts forecast that Glaukos Corporation will post -0.57 EPS for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.